Table 7.
Utility value | Range used in SA | Distribution | Source | |
---|---|---|---|---|
Stable health state | ||||
Mild | 0.82 | 0.8–0.84 | Beta | Pooled indacaterol clinical trials [24] |
Moderate | 0.80 | 0.79–0.81 | Beta | Pooled indacaterol clinical trials [24] |
Severe | 0.77 | 0.77–0.78 | Beta | Pooled indacaterol clinical trials [24] |
Very Severe | 0.74 | 0.73–0.76 | Beta | Pooled indacaterol clinical trials [24] |
Exacerbations | Utility decrement | Source | ||
Non-severe exacerbation | 0.01 | 0–0.024 | Beta | Rutten-van Molken et al. 2009 [26] |
Severe exacerbation | 0.042 | 0.024–0.060 | Beta | Rutten-van Molken et al. 2009 [26] |
SA sensitivity analyses